Method and Device for Using Vibroacoustical Stimulation to Treat Target Tissue Areas of Living Organisms

• US 20090005713A1
• Filed: 09/12/2008
• Published: 01/01/2009
• Est. Priority Date: 02/12/2007
• Status: Abandoned Application

• Current Assignee: Mikhail N. Lyubich, Yury M. Podrazhansky
• Original Assignee: Mikhail N. Lyubich, Yury M. Podrazhansky
• Inventors: Lyubich, Mikhail N., Podrazhansky, Yury M.
• Application Number:
  US12/209,412
• Publication Number:
  US 20090005713A1
• Time in Patent Office: Days
• US Class Current: 601/2
• CPC Class Codes: A61H 2201/165 Wearable interfaces
• CPC Class Codes: A61H 23/0236 using sonic waves, e.g. using loudspeakers

Abstract

A method and device for using topically applied acoustical vibrations to treat diseases and conditions in living organisms. This approach is non-invasive, and more specifically does not involve introducing chemicals or physically invading the organisms. One or more acoustical transducers are placed directly on the skin of the organism in certain locations, and specific vibration profiles designed to treat specific diseases and conditions are applied to the organism through the transducers. The treatment includes the regular application of various vibration pulse profiles that generally include sequences of pulses in which each pulse has a duration in the range of 0.5 to 10 seconds, is separated by rest periods in the range of 0.1 to 3 seconds, is modulated with an oscillatory signal in the frequency range of 1 Hz to 1,500 Hz, and has a pulse amplitude in the range of range from about 20 to 5000 microns.

Claims

1. A method for applying a therapeutic treatment to target tissue areas of a living organism, comprising the steps of:

Placing one or more acoustical transducers on or near the external skin surface overlying or adjacent to the target tissue areas of the living organism;

Causing the acoustical transducers to produce a vibroacoustic signal profile comprising sequences of pulses defining a therapeutic regimen configured to impart a therapeutic effect to counteract a specific disease or condition affecting the target tissue areas;

Wherein the specific disease or condition is selected from the group consisting of multiple sclerosis, migraine headache, benign prostatic hyperplasia, spinal cord injury, peripheral neuropathy, Parkinson'"'"'s disease, and essential tremor;

Wherein each pulse has a duration in the range from approximately one-half of a second to approximately ten seconds, each pulse has an amplitude in the range from approximately 20 microns to approximately 5,000 microns, and adjacent pulses are separated by rest periods in the range from approximately one-tenth of a second to approximately three seconds; and

Wherein the therapeutic regimen comprises one or more modulated frequency passes comprising pulses that are modulated with an oscillatory signal in the frequency range from approximately 3 Hz to approximately 1,200 Hz.

2. The method of claim 1, wherein:

The specific disease or condition comprises multiple sclerosis;

The target tissue areas include a vertebral column area and a head area;

The therapeutic regimen comprises a first application applied to the vertebral column area having a duration between approximately 10 minutes to approximately 60 minutes; and

The therapeutic regimen comprises a second application applied to the head area having duration between approximately 2 minutes to approximately 3 minutes.

3. The method of claim 2, wherein the first application comprises:

A plurality of modulated frequency passes, wherein each modulated frequency pass has duration from approximately 2 minutes to approximately 5 minutes and comprises a plurality of pulses, each pulse having a duration from approximately 2 seconds to approximately 5 seconds and comprising a modulation frequency from approximately 200 Hz to approximately 1100 Hz.

4. The method of claim 3, wherein the second application comprises at least one modulated frequency pass comprising a plurality of pulses, each pulse has a duration from approximately 1 second to approximately 2 seconds and comprises a modulation frequency from approximately 600 Hz to approximately 1100 Hz and each pulse has an amplitude of vibration in the range from approximately 20 microns to approximately 1000 microns.

5. The method of claim 4, further comprising a rest period from approximately 1 minute to approximately 60 minutes between the first application and the second application.

6. The method of claim 5, wherein the therapeutic effect comprises stimulation of growth of adult stem cells in the target tissue areas.

7. The method of claim 1, wherein:

The specific disease or condition comprises migraine headache;

The target tissue areas include head and neck area;

The therapeutic regimen comprises at least one modulated frequency pass having a duration from approximately 0.5 minutes to approximately 3 minutes and comprising a plurality of pulses, each pulse having a duration from approximately 0.5 seconds to approximately 2 seconds and comprising a modulation frequency from approximately 700 Hz to approximately 1100 Hz and each pulse has an amplitude of vibration in the range from approximately 200 microns to approximately 1000 microns.

8. The method of claim 1, wherein:

The specific disease or condition comprises benign prostatic hyperplasia;

The target tissue areas include a pelvic area;

The therapeutic regimen has duration of approximately 15 minutes to approximately 35 minutes and comprises a plurality of modulated high frequency passes and low frequency passes;

Wherein each low frequency pass has a duration of approximately 3 minutes to approximately 5 minutes during which the vibroacoustic signal profile varies in the range from approximately 3 Hz to approximately 100 Hz; and

each pulse has an amplitude of vibration in the range from approximately 500 microns to approximately 5000 microns;

Wherein each high frequency pass has a duration from approximately 3 minutes to approximately 5 minutes and comprises a plurality of pulses, each pulse having a duration of approximately from 1 second to 2 seconds and comprising a modulation frequency from approximately 400 Hz to approximately 1000 Hz and each pulse has an amplitude of vibration in the range from approximately 1000 microns to approximately 5000 microns.

9. The method of claim 1, wherein:

The specific disease or condition comprises spinal cord injury;

The target tissue areas include a vertebral column area;

The therapeutic regimen has duration of approximately 10 minutes to approximately 30 minutes and comprises a plurality of modulated frequency passes;

Wherein each modulated frequency pass comprises a plurality of modulated pulses having amplitude of micro vibration from approximately 300 microns to approximately 5000; and

Wherein each modulated frequency pass has a duration from approximately 2 minutes to approximately 6 minutes and comprises a plurality of pulses, each pulse having a duration from approximately 1 second to approximately 6 seconds and comprising a modulation frequency from approximately 400 Hz to approximately 1200 Hz.

10. The method of claim 1, wherein:

the specific disease or condition comprises peripheral neuropathy;

The target tissue areas include a nerve affected by peripheral neuropathy;

The therapeutic regimen has a duration of approximately 15 minutes to approximately 20 minutes and comprises a plurality of modulated high frequency passes and low frequency passes;

Wherein each low frequency pass comprises a vibroacoustic signal profile in the range from approximately 4 Hz to approximately 40 Hz and amplitude of microvibrations from approximately 500 microns to approximately 4000 microns; and

each pass having a duration from approximately 2 minutes to approximately 3 minutes, and

Wherein each high frequency pass comprising a plurality of pulses, wherein each pulse comprises a modulation frequency from approximately 800 Hz to approximately 1200 Hz and amplitude from approximately 500 microns to approximately 5000 microns, and each pulse having a duration from approximately 0.5 seconds to approximately 1 second;

each pass having a duration from approximately 1 minute to approximately 2 minutes.

11. The method of claim 1, wherein:

The specific disease or condition comprises Parkinson'"'"'s and essential tremor;

disease;

The target tissue areas include a vertebral column area and a head area;

the therapeutic regimen comprises an application comprising a vibroacoustic signal profile in the range from approximately 200 microns to approximately 3000 microns applied to the vertebral column for a duration of not more than approximately 15 minutes to 30 minutes; and

Wherein each modulated frequency pass comprising a plurality of pulses, wherein each pulse comprises a modulation frequency from approximately 500 Hz to approximately 1000 Hz, and each pulse having a duration from approximately 2 seconds to approximately 7 seconds;

The therapeutic regimen comprises a head area application comprising a vibroacoustic signal profile having amplitude of micro vibrations in the range from approximately 100 microns to approximately 1000 microns applied to the head for a duration from approximately 1 minute to approximately 3 minutes, and each pass having a duration from approximately 1 minute to approximately 3 minutes.

12. The method of claim 11, wherein the therapeutic effect comprises stimulation of growth of adult stem cells in the target tissue areas.

13. A method for applying a therapeutic treatment to target tissue areas of a living organism, comprising the steps of:

Placing one or more acoustical transducers on or near the external skin surface overlying or adjacent to the target tissue areas of the living organism;

Causing the acoustical transducers to produce a vibroacoustic signal profile comprising sequences of pulses defining a therapeutic regimen configured to impart a therapeutic effect to counteract a specific disease or condition affecting the target tissue areas.

Wherein the specific disease or condition is selected from the group consisting of functional constipation, urge incontinence, anemia associated with chronic disease, and renal anemia;

Wherein each modulated pulse has a duration in the range from approximately 0.5 seconds to approximately 10 seconds, each pulse has an amplitude in the range from approximately 200 microns to approximately 5,000 microns, and adjacent modulated pulses are separated by rest periods in the range from approximately 0.1 seconds to approximately 3 seconds; and

Wherein the therapeutic regimen comprises one or more modulated and non modulated frequency passes comprising pulses that are modulated with an oscillatory signal in the frequency range from approximately 100 Hz to approximately 1,500 Hz and non modulated oscillatory signal in the range from approximately 1 HZ to approximately 100 Hz.

14. The method of claim 13, wherein:

The specific disease or condition comprises functional constipation characterized by colonic inertia;

The target tissue areas include an abdominal area and a pelvic area;

The therapeutic regimen has a duration of approximately 12 minutes to approximately 25 minutes and comprises a plurality of modulated frequency passes, each modulated frequency pass comprising a plurality of pulses, wherein each pulse has duration from approximately 4 seconds to approximately 10 seconds and comprises a modulation frequency from approximately 300 Hz to approximately 1500 Hz.

15. The method of claim 13, wherein:

The specific disease or condition comprises functional constipation characterized by pelvic floor dysfunction;

The target tissue areas include a crotch area;

The therapeutic regimen has duration of approximately 24 minutes to approximately 26 minutes and comprises a plurality of high frequency passes and a plurality of low frequency passes;

Each high frequency pass a duration from approximately 2.5 minutes to approximately 3 minutes and comprising a plurality of pulses, wherein each pulse comprises a modulation frequency from approximately 200 Hz to approximately 1500 Hz and duration from approximately 3 seconds to approximately 8 second and amplitude of approximately 2000 microns to 5000 microns; and

Each low frequency pass comprises a vibroacoustic signal profile in the range from approximately 1 Hz to approximately 200 Hz, amplitude of approximately 2000 microns to 5000 microns, and duration of at least approximately 5 minutes.

16. The method of claim 13, wherein:

The specific disease or condition comprises functional constipation characterized by ano-rectal dysfunction or anismus;

The target tissue areas include a crotch area;

The therapeutic regimen has duration from approximately 20 minutes to approximately 22 minutes and comprises a plurality of modulated frequency passes;

Each modulated frequency pass has duration of approximately 2 minutes to 3 minutes and comprises a plurality of modulated pulses, wherein each pulse comprises a modulation frequency from approximately 400 Hz to approximately 1500 Hz and amplitude from approximately 100 microns to approximately 2000 microns.

17. The method of claim 13 wherein:

The specific disease or condition comprises urinary urge incontinence;

The target tissue areas include a low abdominal and pelvic area;

The therapeutic regimen has duration of from approximately 18 minutes to approximately 22 minutes and comprises a plurality of high frequency passes and one or more low frequency passes;

Wherein each high frequency pass has a duration from approximately 3 minutes to approximately 4 minutes and comprises a plurality of pulses, wherein each pulse comprises a modulation frequency from approximately 200 Hz to approximately 1500 Hz and amplitude from approximately 100 microns to approximately 500 microns; and

Wherein each low non modulated frequency pass comprises a vibroacoustic signal profile in the range from approximately 3 Hz to approximately 200 Hz, duration from approximately 1 minute to approximately 3 minutes, and amplitude from approximately 200 microns to approximately 2000 microns.

18. A device for applying a therapeutic treatment to target tissue areas of a living organism, comprising:

One or more acoustical transducers configured to be located on or near the external skin surface overlying or adjacent to the target tissue areas of the living organism;

Means for causing the acoustical transducers to produce a vibroacoustic signal profile comprising sequences of pulses defining a therapeutic regimen configured to impart a therapeutic effect to counteract a specific disease or condition affecting the target tissue areas;

Wherein the specific disease or condition is selected from the group consisting of multiple sclerosis, migraine headache, benign prostatic hyperplasia, spinal cord injury, peripheral neuropathy, Parkinson'"'"'s disease, essential tremor, functional constipation, urge incontinence, anemia associated with chronic disease, and renal anemia;

Wherein each pulse has a duration in the range from approximately 1 seconds to approximately 0.08 seconds, each pulse has an amplitude in the range from approximately 20 microns to approximately 5,000 microns, and adjacent modulated pulses are separated by rest periods in the range from approximately 0.1 seconds to approximately 3 seconds; and

Wherein the therapeutic regimen comprises one or more modulated frequency passes comprising pulses that are modulated with an oscillatory signal in the frequency range from approximately 200 Hz to approximately 1,500 Hz and non modulated oscillatory signal in the range from approximately 1 HZ to approximately 100 Hz.

19. The device of claim 18 wherein:

The specific disease or condition is anemia associated with chronic disease or renal anemia;

The target tissue areas include a vertebral column area and pelvic area;

The therapeutic regimen has duration of approximately 15 minutes to approximately 30 minutes and comprises a plurality of modulated frequency passes;

Wherein each modulated frequency pass comprises a plurality of non-modulated pulses having amplitude of micro vibration from approximately 300 microns to approximately 4000; and

Wherein each modulated frequency pass has a duration from approximately 2 to approximately 5 minutes and comprises a plurality of pulses, each modulated pulse having a duration from approximately 1.2 second to approximately 10 seconds and comprising a modulation frequency from approximately 400 Hz to approximately 1300 Hz.

20. The device of claim 18, wherein the therapeutic effect comprises stimulation of growth of adult stem cells in the target tissue areas.